Group 1 - The Guangdong-Hong Kong-Macao Greater Bay Area National Technology Innovation Center International Headquarters has officially settled in the He Tao Science and Technology Innovation Center, aiming to leverage institutional advantages to integrate innovation resources efficiently [1] - The center is a national-level comprehensive results transformation platform jointly deployed by Guangdong Province, Shenzhen City, and Tsinghua University, focusing on key areas such as biomedicine, high-performance materials, and artificial intelligence [1] - The headquarters has been awarded the titles of "Shenzhen Medical-Engineering Integration Results Transformation Demonstration Base" and "Shenzhen Medical Security Bureau Industry Innovation Empowerment Window," and has signed strategic cooperation agreements with local innovation centers and companies [1] Group 2 - The two-year anniversary of the State Council's "He Tao Shenzhen Park Development Plan" highlights the development positioning of the "Greater Bay Area Pilot Transformation Cluster" and the task of building an internationally competitive industrial pilot transformation base [2] - Over the past two years, the He Tao Shenzhen Park has established ten industry-level pilot platforms, including those for new optical materials and automated drug discovery, accelerating the integration of technological and industrial innovation [2]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6][49]. Core Views - The medical services sector has shown a decline of 2.22% this week, underperforming compared to the Shanghai Composite Index, which increased by 1.23% [2][12]. - The report highlights the recent policy support for brain-computer interface technology, indicating potential growth in this area [48]. - The medical services sector's current PE ratio is 37.54, with a historical valuation at the 28.04 percentile, suggesting it is relatively undervalued compared to its historical performance [4][30]. Summary by Sections Industry Performance - The medical services sector reported a decline of 2.22%, with the overall medical and biological sector down by 0.84% [2][24]. - Notable performers in the medical services sector include Nanmo Biology (+42.5%) and Innovative Medical (+18.0%), while underperformers include Kailaiying (-12.1%) and Ruizhi Medicine (-6.6%) [3][29]. Valuation Metrics - The current PE (ttm) for the medical services sector is 37.54, with a historical maximum of 40.26 and a minimum of 20.92 over the past year [4][30]. - The current PB (lf) is 3.50, with historical extremes of 3.77 and 2.06 [4][30]. Industry Dynamics - The 11th batch of national drug centralized procurement has been initiated, with a focus on optimizing reporting rules for medical institutions [46][47]. - Shanghai has introduced measures to promote the high-quality development of commercial health insurance, enhancing the accessibility and affordability of innovative drugs and devices [46][48]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing sector, with companies like WuXi AppTec and Haoyuan Pharmaceutical highlighted [49]. - It also recommends looking at companies with expected improvements in profitability, such as Aier Eye Hospital and Dian Diagnostics [49][50].

Group 1 - The company, Ruizhi Pharmaceutical, focuses on pharmaceutical research and development as well as production services (CRO/CDMO) [1] - The company aims to provide one-stop services for global pharmaceutical enterprises, biotechnology companies, and research institutions, covering both chemical and biological drugs from early discovery to commercial production [1] - Currently, the company's main business does not involve medical devices [1]

Core Insights - RuiZhi Pharmaceutical Technology Co., Ltd. has officially signed a deep strategic cooperation agreement with Guangzhou KENTAI Biopharmaceutical Technology Co., Ltd., establishing a long-term and stable strategic partnership [1] - The collaboration will focus on various critical aspects of innovative drug development, including preclinical research, pharmacodynamics, pharmacokinetics, bioanalysis, safety evaluation, and CDMO [1] - The aim is to explore and construct an ecological model suitable for the rapid development and promotion of domestic innovative drugs [1]

Group 1 - The stock price of Ruizhi Pharmaceutical closed at 12.99 yuan on August 5, down 0.20 yuan, a decrease of 1.52% from the previous trading day [1] - The opening price on August 5 was 13.20 yuan, with a highest point of 13.40 yuan and a lowest point of 12.90 yuan, with a trading volume of 507,056 hands and a transaction amount of 663 million yuan [1] - On the morning of August 5, Ruizhi Pharmaceutical experienced a rapid decline, with a drop of over 2% within 5 minutes, reaching a price of 13.12 yuan at 9:46 AM, with a transaction amount of 175 million yuan [1] Group 2 - The company operates in the medical services industry, focusing on pharmaceutical research and production services, with its registered location in Guangdong Province [1] - The business areas include innovative drugs and recombinant proteins [1] Group 3 - On August 5, the net outflow of main funds was 49.89 million yuan, accounting for 0.77% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 279.62 million yuan, representing 4.33% of the circulating market value [1]

Group 1 - The core point of the article highlights that Ruizhi Pharmaceutical's stock closed at 13.19 yuan on August 4, experiencing a decline of 0.11 yuan, or 0.83% [1] - The trading volume on that day was 719,171 hands, with a total transaction amount of 926 million yuan, and a price fluctuation of 7.67% [1] - The company operates in the healthcare services sector, focusing on innovative drug research and development [1] Group 2 - On August 4, there was a brief rebound in the stock price, with an increase of over 2% within five minutes [1] - Ruizhi Pharmaceutical recently signed a strategic cooperation agreement with Lidao Pharmaceutical to jointly advance the innovative drug development process [1] - Despite a net outflow of 35.62 million yuan from main funds on August 4, there has been a cumulative net inflow of 6.50 million yuan over the past five days [1]

人民财讯8月4日电，近日，上海睿智医药（300149）研究集团有限公司(简称"睿智医药")与上海璃道医 药科技有限公司(简称"璃道医药")正式签署战略合作协议。未来五年内，双方将在药物研究和开发的多 个领域展开合作，包括化学研究、生物学研究、药理药效学研究、药代动力学研究、毒理学研究、药学 研究和临床研究等，共同推进璃道医药新药管线的研发，加快项目从IDEA到NDA的进程。 ...

Group 1: Ruizi Pharmaceutical - Ruizi Pharmaceutical is optimizing its management system and enhancing market marketing and customer expansion under the leadership of CEO Hu [1] - The company has established a "full-package service" development strategy, focusing on one-stop service capabilities from target discovery to IND application [1] - The company has localized its DeepSeek platform for AI applications in experimental data analysis, report generation, and knowledge graph construction [1] - The core competitiveness lies in its deep technical accumulation and comprehensive one-stop service capabilities [1] - The company has no plans to spin off its large molecule CDMO business and has completed long-term asset depreciation and personnel structure optimization [1] - Pharmacology and pharmacokinetics business has surpassed 50% of total revenue, with orders for large molecules slightly exceeding those for small molecules [1] Group 2: Hongfa Co., Ltd. - In the first half of 2025, Hongfa Co., Ltd. achieved high-quality growth with multiple business areas experiencing rapid growth, with per capita revenue reaching 654,000 yuan, an increase of 8.9% year-on-year [2] - Gross margin is significantly influenced by the growth rate of business scale, with continuous improvement in per capita efficiency driving gradual increases in gross margin [2] - The company has solidified its market position with high-quality automotive relay products and has received customer recognition for its high-capacity control box products [2] - The increasing penetration rate of electric vehicles in Europe is expected to benefit the company, with further strengthening of its market layout in Europe [2] - Industrial relays have shown good recovery growth, with a favorable competitive landscape in the industry [2] - The high-capacity control box initially served Toyota and has since expanded to leading domestic automotive manufacturers and battery factories, actively exploring overseas markets [2] - The company has put its production bases in Indonesia and Germany into operation, supported by a core management team with rich experience [2] - The relay business continues to consolidate its leading advantage, with new product categories expected to enter a rapid development track [2] - Order intake and backlog maintain a favorable outlook, with a stable global economic environment likely to sustain good market conditions [2]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [5][9][73] Core Views - The medical services sector is experiencing a positive trend, with a 2.68% increase in the sub-sector index, indicating a stable recovery despite ongoing pressures from medical insurance cost control [11][22][73] - The introduction of new pricing mechanisms by the National Medical Insurance Administration supports the clinical application of innovative technologies such as brain-computer interfaces, which are expected to enhance patient care and recovery [4][63][72] Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 2.95%, outperforming the CSI 300 index by 4.70 percentage points [11][22] - The medical services sub-sector index closed at 6473.29 points, reflecting a 2.68% increase [22][31] Company Performance - Top-performing companies in the medical services sector include Baicheng Pharmaceutical (+23.5%), Ruizhi Pharmaceutical (+15.7%), and Tigermed (+8.1%) [2][28] - Underperforming companies include Haoyuan Pharmaceutical (-6.5%) and Meidi West (-4.9%) [2][28] Valuation Metrics - The current Price-to-Earnings (PE) ratio for the medical services sector is 38.50X, with a Price-to-Book (PB) ratio of 3.61X [3][31] - The PE ratio has increased by 1.02X from the previous week, while the PB ratio has risen by 0.14X [3][31] Industry Dynamics - The National Medical Insurance Administration has introduced over 100 new pricing items related to innovative medical technologies, facilitating faster clinical application and reimbursement [4][63] - The 2025 version of the Chikungunya fever treatment plan has been released, reflecting ongoing efforts to standardize clinical practices [4][65] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and weight-loss drug supply chains, as well as companies with improving profit margins in third-party testing laboratories and consumer healthcare sectors [9][73]

Core Viewpoint - The article highlights the recent performance of A-share listed companies, focusing on significant stock price increases for specific companies amid a generally declining market trend. It emphasizes the importance of institutional research and the potential for growth in certain sectors, particularly in technology and manufacturing. Group 1: Market Performance - During the week of July 28 to August 1, A-share indices experienced fluctuations, with the Shanghai Composite Index falling by 0.94% to close at 3559.95 points, while the Shenzhen Component and ChiNext Index dropped by 1.58% and 0.74%, respectively [2] - Despite the overall market decline, two stocks, Defu Technology and Shenghong Technology, surged over 20%, reaching new highs for the year [3] Group 2: Institutional Research - A total of 125 listed companies disclosed institutional research minutes last week, with nearly 40% of the companies experiencing positive returns. Defu Technology and Shenghong Technology were among those with significant gains, with Defu Technology achieving a year-high stock price [3] Group 3: Defu Technology - Defu Technology (301511) hosted 144 institutional investors for research, the highest number for the week. The interest was driven by the company's plan to acquire 100% of Luxembourg Copper Foil for €1.74 billion, which is noted for its advanced technology and production capabilities [5] - The acquisition will increase Defu Technology's electrolytic copper foil production capacity from 175,000 tons per year to 191,000 tons per year, making it the world's largest producer [5] - The company highlighted a supply shortage in the global HVLP3 and above copper foil market, indicating strong future growth potential [5] Group 4: Shenghong Technology - Shenghong Technology, also in the electronic components sector, announced plans for a Hong Kong IPO to capitalize on global AI opportunities. The company aims to become a leading player in the AI hardware supply chain [6] - The funds raised from the IPO will be used for high-end capacity expansion, smart upgrades, and research in advanced PCB technologies, enhancing the company's global expansion capabilities [8] Group 5: Industry Insights - CIMC Group reported optimistic performance in its container business, driven by favorable US-China trade negotiations and increased demand for container orders, with expectations of industry production exceeding 3 million TEU for the year [9] - CATL disclosed a net profit of 30.5 billion yuan for the first half of the year, a 33.33% increase year-on-year, with a high capacity utilization rate of around 90% [9] - BOE Technology indicated a continued trend of inventory reduction in the LCD TV market, with expectations for price stabilization as demand recovers in August [9]